TIFFANY BARTEK: Open Payments
NPI 1518700475 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$394 in 23 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $248 · 2025 $394
Food & beverage: $394
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $90 |
| AstraZeneca Pharmaceuticals LP | 3 | $50 |
| Astellas Pharma US Inc | 1 | $33 |
| Lilly USA, LLC | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| Amneal Pharmaceuticals LLC | 2 | $31 |
| Novo Nordisk Inc | 2 | $30 |
| BioMarin Pharmaceutical Inc. | 1 | $22 |
| Merck Sharp & Dohme LLC | 1 | $17 |
| Janssen Pharmaceuticals, Inc | 1 | $17 |
Products named: VRAYLAR, Veozah, MOUNJARO, UBRELVY, REXULTI, UNITHROID, VOXZOGO 1.2mg, VIBERZI.
Industry payments across NE — which companies pay providers there.
